ERBB2 and metastatic neoplasm: The discordance of ER, PR, and HER2 expression between primary tumors and recurrent or metastatic tumors have been widely reported and theories regarding the mechanism underlying these changes include the variability of detection performance, tumor heterogeneity, the organ microenvironment, and biological evolution [27–29].